ATRC on Nasdaq
AtriCure (United States)
Company in Sharonville, United States.1
$57.08 down 0.23 (0.39%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 16, 2026.
Overview
2000Founded1
Compare with GLAUKOS Corp, Bioventus Inc. or UFP Technologies, or pick any stock.
- TickerATRC on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersSharonville1
- Websitewww.atricure.com
- Incorporated inDE4
- Business address7555 Innovation Way, Mason, Oh 450404
- Filer categoryLarge accelerated filer4
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
75.0%Gross margin6
-1.8%Operating margin6
-2.1%Net margin6
14.9%Revenue growth, 20256
-2.3%Return on equity6
0.13×Debt to equity6
$48.3MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 81% of the revenue AtriCure (United States) broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $333.5M | $382.8M | $435.4M |
| Europe | $38.5M | $49.9M | $61.5M |
| Asia Pacific | $24.5M | $27.4M | $30.7M |
| Other International | $2.7M | $5.2M | $6.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue25¢$133.7M
- Research and development18¢$99.2M
- Selling, general and admin57¢$311.0M
- Income tax0¢$1.3M
Out of $534.5M in revenue.6 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending16¢$9.1M
- Kept or used elsewhere84¢$48.3M
Out of $57.3M of cash from operations.6
Financial statements
Every line of the income statement in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $534.5M | $465.3M | $399.2M |
| Cost of revenue | $133.7M | $117.8M | $98.9M |
| Gross profit | $400.8M | $347.5M | $300.4M |
| Research and development expenses | $99.2M | $96.2M | $73.9M |
| Selling, general and administrative expenses | $311.0M | $291.4M | $253.1M |
| Total operating expenses | $410.2M | $387.5M | $327.1M |
| Loss from operations | -$9.4M | -$40.0M | -$26.7M |
| Interest expense | -$5.9M | -$6.4M | -$6.9M |
| Interest income | $4.5M | $4.4M | $3.8M |
| Loss on debt extinguishment | $0 | -$1.4M | $0 |
| Other income (expense) | $683.0K | -$326.0K | -$31.0K |
| Loss before income tax expense | -$10.2M | -$43.7M | -$29.8M |
| Income tax expense | $1.3M | $1.0M | $591.0K |
| Net loss | -$11.4M | -$44.7M | -$30.4M |
| Basic net loss per share (in usd per share) | -$0.24 | -$0.95 | -$0.66 |
| Diluted net loss per share (in usd per share) | -$0.24 | -$0.95 | -$0.66 |
| Weighted average shares outstanding, basic (in shares) | 47.8M shares | 47.0M shares | 46.3M shares |
| Weighted average shares outstanding, diluted (in shares) | 47.8M shares | 47.0M shares | 46.3M shares |
| Unrealized gain on investments | $0 | $800.0K | $2.9M |
| Foreign currency translation adjustment | $1.6M | -$842.0K | $205.0K |
| Other comprehensive income (loss) | $1.6M | -$42.0K | $3.1M |
| Comprehensive loss, net of tax | -$9.8M | -$44.7M | -$27.3M |
Every line of the balance sheet in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $167.4M | $122.7M | |
| Accounts receivable, less allowance for credit losses of $750 and $550 | $66.7M | $60.3M | |
| Inventories | $78.5M | $75.3M | |
| Prepaid and other current assets | $9.9M | $9.4M | |
| Total current assets | $322.5M | $267.8M | |
| Property and equipment, net | $39.1M | $41.7M | |
| Operating lease right-of-use assets | $6.9M | $5.7M | |
| Intangible assets, net | $48.0M | $56.5M | |
| Goodwill | $234.8M | $234.8M | $234.8M |
| Other noncurrent assets | $2.9M | $2.9M | |
| Total Assets | $654.2M | $609.3M | |
| Accounts payable | $25.3M | $25.0M | |
| Accrued liabilities | $53.1M | $45.6M | |
| Other current liabilities | $3.1M | $2.8M | |
| Total current liabilities | $81.5M | $73.4M | |
| Long-term debt | $61.9M | $61.9M | $61.0M |
| Finance and operating lease liabilities | $11.5M | $11.9M | |
| Other noncurrent liabilities | $7.3M | $1.2M | |
| Total Liabilities | $162.2M | $148.4M | |
| Common stock, $0.001 par value, 90,000 shares authorized; 49,792 and 48,869 issued and outstanding | $50.0K | $49.0K | |
| Additional paid-in capital | $904.5M | $863.7M | |
| Accumulated other comprehensive income (loss) | $566.0K | -$1.0M | |
| Accumulated deficit | -$413.2M | -$401.8M | |
| Total Stockholders Equity | $491.9M | $461.0M | $466.2M |
| Total Liabilities and Stockholders Equity | $654.2M | $609.3M | |
| Accounts receivable, allowance for credit losses | $750.0K | $550.0K | |
| Common stock, par value (in usd per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 90.0M shares | 90.0M shares | |
| Common stock, shares issued (in shares) | 49.8M shares | 48.9M shares | |
| Common stock, shares outstanding (in shares) | 49.8M shares | 48.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$11.4M | -$44.7M | -$30.4M |
| Share-based compensation expense | $44.7M | $40.4M | $35.7M |
| Depreciation | $12.1M | $11.2M | $9.5M |
| Amortization of intangible assets | $8.4M | $7.5M | $5.4M |
| Amortization of deferred financing costs | $478.0K | $478.0K | $486.0K |
| Amortization of investments | $0 | $107.0K | $632.0K |
| Acquired in-process research and development expense | $6.0M | $12.0M | $0 |
| Loss on debt extinguishment | $0 | $1.4M | $0 |
| Other non-cash adjustments | $1.4M | $2.2M | $1.5M |
| Accounts receivable | -$5.6M | -$8.3M | -$9.9M |
| Inventories | -$2.3M | -$7.7M | -$21.8M |
| Other current assets | -$328.0K | -$949.0K | -$3.1M |
| Accounts payable | -$960.0K | -$1.5M | $6.2M |
| Accrued liabilities | $7.0M | $1.2M | $11.6M |
| Other noncurrent assets and liabilities | -$2.1M | -$1.0M | -$1.2M |
| Net cash provided by operating activities | $57.3M | $12.2M | $4.5M |
| Sales and maturities of available-for-sale securities | $0 | $53.7M | $63.8M |
| Purchases of property and equipment | -$9.1M | -$11.5M | -$12.0M |
| Proceeds from sale of property and equipment | $0 | $25.0K | $0 |
| Acquisitions, including in-process research and development | -$6.0M | -$12.0M | -$30.0M |
| Proceeds from capital grant | $500.0K | $0 | $0 |
| Net cash (used in) provided by investing activities | -$14.6M | $30.2M | $21.8M |
| Proceeds from revolving credit facility, net of financing costs | $0 | $61.2M | $0 |
| Payments on debt, leases and financing obligation | -$1.2M | -$62.9M | -$992.0K |
| Proceeds from financing obligation | $6.2M | $0 | $0 |
| Payment of financing costs and bank fees | $0 | -$1.1M | -$60.0K |
| Proceeds from stock option exercises | $1.4M | $1.0M | $2.3M |
| Shares repurchased for payment of taxes on stock awards | -$11.2M | -$7.0M | -$6.6M |
| Proceeds from issuance of common stock under employee stock purchase plan | $5.9M | $5.1M | $5.3M |
| Net cash provided by (used in) financing activities | $1.2M | -$3.6M | -$32.0K |
| Effect of exchange rate changes on cash and cash equivalents | $747.0K | -$424.0K | -$58.0K |
| Net increase in cash and cash equivalents | $44.7M | $38.4M | $26.2M |
| Cash paid for interest | $5.3M | $6.0M | $6.4M |
| Cash paid for income taxes, net of refunds | $1.3M | $619.0K | $395.0K |
| Accrued purchases of property and equipment | $1.3M | $334.0K | $1.4M |
Timeline
- 2000Founded Founded1
Recent filings
- Oct 5, 2026SCHEDULE 13G/A
- Sep 24, 20264
- Sep 23, 2026144
- Sep 14, 20264
- Sep 11, 2026144
- Sep 10, 20264
- Sep 8, 2026144
- Sep 4, 20264
- Sep 2, 2026144
- Aug 26, 20264
- Aug 24, 2026144
- Aug 14, 2026SCHEDULE 13G/A
- Aug 7, 20264
- Aug 7, 20264
- Aug 5, 2026144
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.atricure.com1
- WikidataQ30256881
- SEC EDGARCIK 1323885
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Yahoo FinanceATRC quote
- 4
- 5Company websiteAtriCure (United States) photo
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13